3B Blackbio DX Ltd
NSE: 3BBLACKBIO BSE: 532067Chemicals
Incorporated in 2011, 3B BlackBio Dx Ltd manufactures and exports PCR based Molecular Diagnostic kits, PCR Enzymes & PCR Reagents, and agrochemical-based products[1]
₹1,305
52W: ₹1110 — ₹2020
PE 21.9 · Book ₹346 · +277% vs bookMarket Cap₹1,120 Cr
Stock P/E21.9Price to Earnings
ROCE25.5%Return on Capital
ROE19%Return on Equity
Div. Yield0.29%Face Value ₹10
Strengths
- +Company has reduced debt.
- +Company is almost debt free.
- +Company has delivered good profit growth of 139% CAGR over last 5 years
- +Debtor days have improved from 179 to 142 days.
Weaknesses
- −Earnings include an other income of Rs.17.8 Cr.
Shareholding Pattern
Promoters40.94%
FIIs2.57%
DIIs1.98%
Public54.5%
| Category | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 41.28% | 41.28% | 41.28% | 41.28% | 41.28% | 41.28% | 41.27%▼0.0 | 40.94%▼0.3 |
| FIIs | 3.28% | 3.27%▼0.0 | 2.68%▼0.6 | 2.49%▼0.2 | 2.7%▲0.2 | 2.64%▼0.1 | 2.57%▼0.1 | 2.57% |
| DIIs | 1.96% | 1.96% | 1.74%▼0.2 | 1.6%▼0.1 | 1.76%▲0.2 | 1.82%▲0.1 | 1.87%▲0.1 | 1.98%▲0.1 |
| Public | 53.48% | 53.48% | 54.29%▲0.8 | 54.64%▲0.4 | 54.28%▼0.4 | 54.26%▼0.0 | 54.27%▲0.0 | 54.5%▲0.2 |
Financial Statements
| Metric | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 19 | 17 | 22 | 18 | 27 | 23 | 23 | 20 | 28 | 24 |
| Expenses | 10 | 7 | 12 | 7 | 11 | 8 | 14 | 9 | 12 | 10 |
| Operating Profit | 9 | 10 | 10 | 10 | 15 | 15 | 9 | 12 | 16 | 14 |
| OPM % | 47% | 57% | 46% | 59% | 57% | 64% | 41% | 57% | 57% | 59% |
| Net Profit | 8 | 9 | 9 | 11 | 14 | 13 | 9 | 12 | 15 | 14 |
| EPS ₹ | 11.29 | 10.73 | 10.56 | 12.5 | 16.48 | 15.67 | 10.77 | 14.52 | 17.41 | 16.85 |
AI Insights
Revenue Trend
TTM revenue at ₹96Cr, up 5.5% YoY. OPM at 54%.
Debt Position
Borrowings at ₹0Cr. Debt-to-equity ratio: 0.00x. Healthy balance sheet.
Institutional Flow
DIIs: 1.98% (+1.98pp change). FIIs: 2.57% (-0.49pp change). Promoters hold 40.94%.
Margin & Efficiency
ROCE improving from 7% (Mar 2014) to 26% (Mar 2025). Working capital days: 174.
Valuation
PE 21.9x with 25.5% ROCE. Price is 277% above book value of ₹346. Dividend yield: 0.29%.
Recent Announcements
- Announcement under Regulation 30 (LODR)-Newspaper Publication 14 May - Special Window for Re-lodgement of Transfer Requests of Physical Shares
- Securities Of The Companies Permitted To Trade And Admitted To Dealings On The National Stock Exchange 21 Apr - 3B BlackBio Dx shares admitted for NSE trading from April 20, 2026.
- Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2 15 Apr - Company confirmed it is not a Large Corporate under SEBI disclosure norms.
- Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2 15 Apr - Company confirms it is not a Large Corporate under SEBI circular.
- Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A 14 Apr - 3B BlackBio Dx confirms it is not a Large Corporate under SEBI circular.
- Financial Year 2025 from bse
- Financial Year 2024 from bse
- Financial Year 2023 from bse